

#### Public assessment summary report

Name of the Finished Pharmaceutical
Product

Utrogestan Vaginal 100 mg Soft capsules
Utrogestan Vaginal 200 mg Soft capsules

Manufacturer of the Finished Product

Cyndea Pharma Spain Poligono Industrial Emiliano Revilla
Sanz Avenida de Agreda, 31 Olvega 42110 (Soria), Spain

License holder BESINS MANUFACTURING BENELUX

Avenue Louise, 287 1050 Brussels

Belgium

Active Pharmaceutical Ingredient progesterone

(API)

#### 1. Introduction

Based on review of quality, safety and efficacy data through the abbreviated approval procedure, the authority granted a marketing authorization for Utrogestan Vaginal 100 mg Soft capsules and Utrogestan Vaginal 200 mg Soft capsules.

Utrogestan is indiacted for subfertility or primary/secondary infertility due to partial or total luteal phase deficiency (in particular: poor ovulation, supplementation of the luteal phase during *in vitro* fertilisation, egg donations) and threat of miscarriage or prevention of recurrent miscarriages due to luteal phase deficiency.

## 2. Assessment of quality

GMP compliance of the API manufacture was demonstrated by document review. The necessary waiver for cGMP of the finished pharmaceutical product manufacturer has been carried out. Marketing authorization was granted by the stringent regulatory authority (SRA) and appropriate verification of marketing authorization was performed.

### Stability testing:

It is confirmed that the finished product stability studies were conducted in the container closure system proposed for the marketing of the product in accordance with the current medicine registration guideline of Ethiopia. The packaged product was stored at the long term condition of 30°C/75% RH and at the accelerated condition of 40°C/75% RH. The packaging components used are the same as those for proposed commercial package for the marketed product. Based on the data presented, shelf life of 36 months was proposed.







### 3. Conclusion

Based on assessment of administrative and technical document, it is considered that the benefit—risk profile of Utrogestan Vaginal 100 mg and 200 mg Soft capsules are acceptable for the following indications: for subfertility or primary/secondary infertility due to partial or total luteal phase deficiency (in particular: poor ovulation, supplementation of the luteal phase during *in vitro* fertilisation, egg donations) and threat of miscarriage or prevention of recurrent miscarriages due to luteal phase deficiency.






- \* El Cliente será responsable de los contenidos aprobados en el diseño, texto y colores del prospecto, aluminio y estuche. Por tanto, el Cliente será quien se hará cargo de cualquier reclamación, coste y/o gasto referente a la falta de exactitud y precisión de dicha información, y eximirá y mantendrá indemne a CYNDEA PHARMA en relación a cualquier tipo de reclamación, pago y/o gasto referente a la exactitud y precisión de dicha información.
- \* Client shall be responsible for the contents of the artworks approved, text and colours of the leaflets, aluminium foil, and cartons. Therefore, Client shall bear any and all cost and/or expense, and it shall keep CYNDEA PHARMA harmless from any claim, cost and/or expenses, relating to the curreciness and accuracy of such information.






# Utrogestan 100mg/30capsules (VAGINAL) ETIOPÍA - GHANA - KENIA - RUANDA - TANZANIA - UGANDA

Código	Laetus	Versión	Fecha	Descripción de Cambios / Modificaciones	Orden
600501	922	01	24.03.2017	1. Diseño inicial.	BESINS
		02	05.04.2017	Leyenda. Adición de países (códigos ISO internacionales y nombres de países).	CYNDEA
		03	11.04.2017	1. Modificación de dimensiones de estuche. Antes: 56x36x92mm. Ahora: 56x26x92mm.	CYNDEA
		04	16.05.2017	Cara IV. Cambio en los datos de titular de comercialización "MA Holder"	BESINS



- \* El Cliente será responsable de los contenidos aprobados en el diseño, texto y colores del prospecto, aluminio y estuche. Por tanto, el Cliente será quien se hará cargo de cualquier reclamación, coste y/o gasto referente a la falta de exactitud y precisión de dicha información, y eximirá y mantendrá indemne a CYNDEA PHARMA en relación a cualquier tipo de reclamación, pago y/o gasto referente a la exactitud y precisión de dicha información.
- \* Client shall be responsible for the contents of the artworks approved, text and colours of the leaflets, aluminium foil, and cartons. Therefore, Client shall bear any and all cost and/or expense, and it shall keep CYNDEA PHARMA harmless from any claim, cost and/or expenses, relating to the curreciness and accuracy of such information.





# Utrogestan 200mg/15capsules (VAGINAL) ETIOPÍA - GHANA - KENIA - RUANDA - TANZANIA - UGANDA

Código	Laetus	Versión	Fecha	Descripción de Cambios / Modificaciones	Orden
600502	923	01	24.03.2017	1. Diseño inicial. Procedencia/Similitud: 600171/365, v01 de09/05/2014.	BESINS
		02	05.04.2017	Leyenda. Adición de países (códigos ISO internacionales y nombres de países).	CYNDEA
		03	11.04.2017	1. Modificación de dimensiones de estuche. Antes: 56x36x92mm. Ahora: 56x26x92mm.	CYNDEA
		04	16.05.2017	Cara IV. Cambio en los datos de titular de comercialización "MA Holder"	BESINS